Eli Lilly agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion, seeking to deepen its neuroscience pipeline ahead of Phase 3 momentum in treatment-resistant depression. AtaiBeckley’s lead asset, BPL-003 (mebufotenin benzoate), has FDA Breakthrough Therapy designation and is in late-stage development.